

Electromed, Inc. (ELMD)

NYSE; healthcare; SIC 3845, Electromedical & Electrotherapeutic Apparatus; CIK 0001488917

Electromed, Inc. ELMD; healthcare	
Grade	A ▼ A B C D E strongest fifth of 371 graded peers percentile 3.8; sampling error 2.5 points; lower is stronger
Rank	15 of 371
Profitability	B percentile 36.2
Solvency	B percentile 23.6
Growth and financing	B percentile 28.2
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$66.3M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Aug 25, 2026 45 days before the rescans; latest periodic filing 10-K received Aug 25, 2026
Last close	\$27.87 2026-10-08; market equity \$233.2M
Price used in grade	None




A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B from Mar 21, 2018, B/C from Feb 21, 2019, B from Mar 21, 2019, A from Sep 2, 2019

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Aug 25, 2026

Electromed, Inc. ("we," "our," "us," "Electromed" or the "Company") develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest® Airway Clearance System ("SmartVest System") to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation ("HFCWO") treatments as effective, convenient, and comfortable as possible, so our patients can

breathe easier and live better with improved respiratory function and fewer exacerbations.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 36.2						
Gross profitability		87.4%	32.2%	5.9	372	2026-06-30
Return on invested capital		not computable	9.3%			latest aligned inputs end 2015-06-30; latest annual assets end 2026-06-30
Accruals ratio		2.7%	(6.6%)	84.8	811	2026-06-30
Gross margin stability, five years		1.2 pts	2.8 pts	17.8	243	2026-06-30
Solvency, sleeve percentile 23.6						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		11.89	(0.31)	7.5	756	2026-06-30
Net debt to EBITDA		not computable	1.82x			latest aligned inputs end 2015-06-30; latest annual assets end 2026-06-30
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		4.69x	2.96x	39.6	839	2026-06-30
Growth and financing, sleeve percentile 28.2						
Revenue growth, three-year compound		15.4%	10.0%	38.9	415	2026-06-30
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		99.9%	37.1%	32.0	104	2026-06-30
Asset growth, three years		13.1%	2.1%	27.6	704	2026-06-30
Net share issuance, one year		0.2%	2.5%	14.2	634	2026-08-19


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 2,347,240 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
10	Iradimed Corp. (IRMD)	2.4	A	
11	Castle Biosciences Inc. (CSTL)	2.7	A	fortress
				balance sheet
12	Penumbra Inc. (PEN)	3.0	A	
13	Lemaitre Vascular Inc. (LMAT)	3.2	A	
14	Corcept Therapeutics Inc. (CORT)	3.5	A	fortress
				balance sheet
15	Electromed, Inc. (ELMD) <	3.8	A	fortress
				balance sheet
16	Tactile Systems Technology Inc. (TCMD)	4.1	A	fortress
				balance sheet
17	Ideaya Biosciences, Inc. (IDYA)	4.3	A	
18	Vericel Corp. (VCEL)	4.6	A	
19	Tarsus Pharmaceuticals, Inc. (TARS)	4.9	A	fortress
				balance sheet
20	Biomarin Pharmaceutical Inc. (BMRN)	5.1	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	13.9%	8.0%	54
Distance from 52-week high	(40.0%)	(31.4%)	38
EBIT to enterprise value	6.5%	(1.5%)	84
Free cash flow yield	3.6%	(1.0%)	72
Book value to price	0.23	0.28	45
Sales to price	0.32	0.31	51
Composite equity issuance, five years	(2.6%)	20.3%	23
Relative strength against the sector, log excess return	(0.08)	(0.14)	54

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$20.4M

Operating cash flow, four quarters	\$9.7M
Months of runway	not finite
Days since last periodic filing	45 (10-K received Aug 25, 2026)
Median daily dollar volume, 63 sessions	\$2.7M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$57.9M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
2	assets	us-gaap:Assets	\$66.3M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
3	operating income	us-gaap:OperatingIncomeLoss	\$1.3M	2015-06-30	2016-09-06	10-K	0000897101-16-002894
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$1.3M	2015-06-30	2016-09-06	10-K	0000897101-16-002894
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$132,000	2015-06-30	2016-09-06	10-K	0000897101-16-002894
6	total debt	us-gaap:LongTermDebt	\$1.3M	2015-06-30	2016-09-06	10-K	0000897101-16-002894
7	book equity	us-gaap:StockholdersEquity	\$13.9M	2015-06-30	2017-09-05	10-K	0000897101-17-001106
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$3.6M	2015-06-30	2015-09-15	10-K	0000897101-15-001220
9	total debt	us-gaap:LongTermDebt	\$1.3M	2014-06-30	2015-09-15	10-K	0000897101-15-001220
10	book equity	us-gaap:StockholdersEquity	\$12.7M	2014-06-30	2015-09-15	10-K	0000897101-15-001220
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.5M	2014-06-30	2015-09-15	10-K	0000897101-15-001220
12	net income	us-gaap:NetIncomeLoss	\$11.3M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$9.7M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
14	assets	us-gaap:Assets	\$53.8M	2025-06-30	2026-08-25	10-K	0001437749-26-028914
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$73.8M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
16	gross profit	us-gaap:GrossProfit	\$50.0M	2025-06-30	2026-08-25	10-K	0001437749-26-028914
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$64.0M	2025-06-30	2026-08-25	10-K	0001437749-26-028914
18	gross profit	us-gaap:GrossProfit	\$41.7M	2024-06-30	2025-08-26	10-K	0001437749-25-027761
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$54.7M	2024-06-30	2025-08-26	10-K	0001437749-25-027761
20	gross profit	us-gaap:GrossProfit	\$36.5M	2023-06-30	2024-08-27	10-K	0000897101-24-000422
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$48.1M	2023-06-30	2024-08-27	10-K	0000897101-24-000422
22	gross profit	us-gaap:GrossProfit	\$31.4M	2022-06-30	2023-08-22	10-K	0000897101-23-000380
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$41.7M	2022-06-30	2023-08-22	10-K	0000897101-23-000380
24	current assets	us-gaap:AssetsCurrent	\$57.4M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
25	current liabilities	us-gaap:LiabilitiesCurrent	\$12.2M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$28.6M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
27	operating income	us-gaap:OperatingIncomeLoss	\$13.9M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
28	book equity	us-gaap:StockholdersEquity	\$54.0M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
29	liabilities	us-gaap:Liabilities	\$12.3M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
30	depreciation amortization	us-gaap:Depreciation	\$613,304	2015-06-30	2016-09-06	10-K	0000897101-16-002894
31	interest expense	us-gaap:InterestExpense	\$85,710	2015-06-30	2015-09-15	10-K	0000897101-15-001220
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.3M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$11.4M	2025-06-30	2026-08-25	10-K	0001437749-26-028914
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$262,000	2025-06-30	2026-08-25	10-K	0001437749-26-028914
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$9.1M	2024-06-30	2025-08-26	10-K	0001437749-25-027761
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$287,000	2024-06-30	2025-08-26	10-K	0001437749-25-027761
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.3M	2023-06-30	2024-08-27	10-K	0000897101-24-000422
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.6M	2023-06-30	2024-08-27	10-K	0000897101-24-000422
39	depreciation amortization	us-gaap:Depreciation	\$868,000	2026-06-30	2026-08-25	10-K	0001437749-26-028914
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$11.4M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
41	income tax	us-gaap:IncomeTaxExpenseBenefit	\$3.1M	2026-06-30	2026-08-25	10-K	0001437749-26-028914
42	current assets	us-gaap:AssetsCurrent	\$45.1M	2025-06-30	2026-08-25	10-K	0001437749-26-028914
43	current liabilities	us-gaap:LiabilitiesCurrent	\$10.5M	2025-06-30	2026-08-25	10-K	0001437749-26-028914
44	assets	us-gaap:Assets	\$52.2M	2024-06-30	2025-08-26	10-K	0001437749-25-027761
45	assets	us-gaap:Assets	\$45.8M	2023-06-30	2024-08-27	10-K	0000897101-24-000422
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,366,163	2026-08-19	2026-08-25	10-K	0001437749-26-028914
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,349,176	2025-08-20	2025-08-26	10-K	0001437749-25-027761